Table 3

HRs (and 95% CIs) of functional limitations for mortality stratified by tumour stage and body mass index*

Other-cause mortality (number of deaths=436)Breast cancer mortality (number of deaths=317)
BaselineDeclineBaselineDecline
Stage of breast cancer at diagnosis*
Local, N=523Number of deaths=274Number of deaths=93
 Functional limitations (continuous)1.11 (1.03 to 1.19)1.07 (0.94 to 1.23)1.04 (0.92 to 1.17)1.16 (0.97 to 1.38)
 Functional limitations (≥1 vs 0)1.46 (1.05 to 2.03)1.06 (0.75 to 1.49)1.30 (0.76 to 2.23)1.02 (0.59 to 1.77)
Regional and remote, N=452Number of deaths=162Number of deaths=224
 Functional limitations (continuous)1.03 (0.94 to 1.14)1.19 (1.00 to 1.43)1.02 (0.94 to 1.10)1.08 (0.92 to 1.26)
 Functional limitations (≥1 vs 0)1.58 (0.90 to 2.75)1.61 (1.03 to 2.52)0.66 (0.47 to 0.93)1.19 (0.82 to 1.73)
Body mass index at baseline, (kg/m2)†
<25, N=454Number of deaths=210Number of deaths=128
 Functional limitations (continuous)1.11 (1.01 to 1.22)1.12 (0.94 to 1.32)1.01 (0.90 to 1.14)1.13 (0.94 to 1.36)
 Functional limitations (≥1 vs 0)1.80 (1.14 to 2.84)1.45 (0.93 to 2.27)0.74 (0.46 to 1.18)1.00 (0.57 to 1.73)
25–30, N=323Number of deaths=148Number of deaths=109
 Functional limitations (continuous)1.07 (1.02 to 1.13)1.10 (1.00 to 1.21)0.99 (0.93 to 1.06)1.17 (1.05 to 1.31)
 Functional limitations (≥1 vs 0)1.48 (1.13 to 1.94)1.24 (0.95 to 1.60)0.71 (0.54 to 0.95)1.28 (0.94 to 1.73)
>30, N=198Number of deaths=78Number of deaths=80
 Functional limitations (continuous)0.78 (0.60 to 1.02)1.09 (0.68 to 1.76)1.08 (0.92 to 1.27)1.48 (1.09 to 2.02)
 Functional limitations (≥1 vs 0)0.62 (0.18 to 2.12)2.15 (0.70 to 6.60)1.50 (0.61 to 3.66)3.05 (1.32 to 7.03)
  • *Models were stratified by age at breast cancer diagnosis and additionally adjusted for race, comorbidity, breast cancer treatment, body mass index, financial adequacy, education, smoking, positive lymph node involvement, tumour size at diagnosis and period of study entry.

  • †Models were stratified by age at breast cancer diagnosis and additionally adjusted for race, comorbidity, breast cancer stage, treatment, financial adequacy, education, smoking, positive lymph node involvement, tumour size at diagnosis and period of study entry.